查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372845

生物皮膚替代品市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、按應用、最終用戶、地區和競爭細分

Biological Skin Substitutes Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Application, By End User, Region and Competition
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，生物皮膚替代品市場估值達到 4.0309 億美元，預計將在預測期內實現強勁成長，預計到 2028 年年複合成長率 (CAGR) 為 8.08%。這種成長可歸因於多種因素造成，包括慢性傷口發生率不斷上升、老年人口不斷增加以及再生醫學技術的日益採用。

近年來，生物皮膚替代品市場顯著擴張，預計這一趨勢將在整個預測期內持續存在。這些替代品可用於治療各種傷口，包括燒傷、糖尿病足潰瘍和手術傷口。它們由多種材料製成，從動物和人體組織到合成材料及其組合。

刺激生物皮膚替代品市場成長的一個重要促進因素是慢性傷口的發生率不斷上升，特別是在老年人口中普遍存在。慢性傷口的治療具有挑戰性，並且經常需要超越傳統傷口護理方法的干涉措施以促進正確癒合。同時，對先進傷口護理產品的需求不斷成長，旨在提高癒合效果並降低整體護理成本。

市場概況
預測期 2024-2028
2022 年市場規模 40309萬美元
2028 年市場規模 64413萬美元
2023-2028 年年複合成長率 8.08%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

此外，再生醫學方法的日益普及促進了生物皮膚替代品市場的擴大。再生醫學利用幹細胞和其他生物實體來促進組織再生和修復。隨著再生醫學領域的進步，生物皮膚替代品的使用將變得更加普遍。

越來越多採用再生醫學技術

再生醫學技術的不斷採用對全球生物皮膚替代品市場的擴大產生了深遠的影響。再生醫學包括利用幹細胞、生長因子和其他生物成分來刺激組織的再生和修復。

隨著再生醫學技術的應用變得越來越普遍，生物皮膚替代品的需求預計將激增。這些產品在眾多再生醫學策略中發揮關鍵作用，並經常被用來為組織的復興和修復提供結構框架。

人們對再生醫學技術日益濃厚的興趣正在推動該領域研究和開發的投資增加。這種動力正在推動創新，最終創造出新型和增強型生物皮膚替代品，為組織再生和修復提供卓越的支持。

再生醫學技術的採用有望擴大生物皮膚替代品的綜合市場。這種擴展背後的理由是，這些技術被用來解決更廣泛的疾病，從慢性傷口和燒傷到重建手術。

再生醫學技術的應用，包括生物皮膚替代品的使用，與增強的復健效果密切相關。這些產品已被證實可以刺激組織再生和修復，有助於加快患者的恢復期並改善功能結果。

此外，再生醫學技術，包括使用生物皮膚替代品，通常與成本效益有關。透過刺激組織更新和修復，這些產品有可能減少更複雜和更昂貴的干涉措施的必要性，例如皮膚移植和重建手術。再生醫學技術日益成長的吸引力正在顯著影響全球生物皮膚替代品市場的發展軌跡。隨著這些技術更廣泛的整合，對生物皮膚替代品的需求預計將增加，從而催化創新並促進這些產品整體市場的擴張。

慢性傷口的發生率不斷上升

慢性傷口盛行率的不斷上升是影響生物皮膚替代品全球市場擴張的關鍵決定因素。慢性傷口是指癒合時間較長且構成重大全球健康問題的傷口。它們可能由多種因素引起，包括糖尿病、血液循環障礙和壓瘡。在解決慢性傷口方面，生物皮膚替代品正受到越來越多的關注，並被認為是應對這項挑戰的有希望的補救措施。

隨著慢性傷口發生頻率的激增，對有效治療替代方案的需求也隨之增加。在此背景下，生物皮膚替代品成為一種可行的解決方案，隨著醫療服務提供者尋求管理慢性傷口的創新途徑，生物皮膚替代品逐漸在醫療保健領域獲得關注。

技術創新正在推動新型、增強型生物皮膚替代品的開發，這些替代品擅長促進組織再生和修復。這個變革過程正在激發市場創新，並導致產品配方在解決慢性傷口方面表現出更高的有效性。

慢性傷口盛行率的增加正在導致生物皮膚替代品整體市場的擴大。這些產品被用來治療日益多樣化的疾病，包括壓瘡、糖尿病足潰瘍和腿部靜脈潰瘍。

生物皮膚替代品已證明其能夠刺激組織再生和修復，從而最終改善患有慢性傷口的個體的癒合結果。這種增強可以使患有這些疾病的患者恢復得更快並提高生活品質。

此外，在慢性傷口處理中使用生物皮膚替代品可以為醫療保健提供者帶來經濟效益。這些產品有可能減少更具侵入性和成本高昂的干涉措施的必要性，例如皮膚移植和重建手術。

慢性傷口發生率的不斷上升是推動全球生物皮膚替代品市場發展的重要影響因素。隨著對有效治療替代方案的追求不斷增強，醫療保健提供者擴大將生物皮膚替代品作為有利的解決方案。

市場區隔

全球生物皮膚替代品市場可以根據類型、應用、最終用戶和地區進行細分。根據類型，市場可進一步分為人類供體組織衍生產品、無細胞動物衍生產品和生物合成產品。根據應用，市場進一步分為慢性傷口和急性傷口。根據最終用戶，市場分為醫院和診所、門診護理中心等。依地區分類，市場分為北美、歐洲、亞太地區、南美、中東和非洲。

市場參與者

Smith & Nephew, plc、3M Company、Organogenesis, Inc.、Stratatech Corporation、Integra LifeSciences Corporation、Tissue Regenix Group、Mimedx Group 是全球生物皮膚替代品市場的一些領先參與者。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球生物皮膚替代品市場還分為以下幾類：

生物皮膚替代品市場，按類型：

  • 人類供體組織衍生產品
  • 無細胞動物衍生產品
  • 生物合成產品

生物皮膚替代品市場，按應用：

  • 慢性傷口
  • 急性傷口

生物皮膚替代品市場，按最終用戶分類：

  • 醫院和診所
  • 門診護理中心
  • 其他

競爭格局

  • 公司概況：全球生物皮膚替代品市場主要公司的詳細分析。

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球生物皮膚替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（人類供體組織衍生產品、無細胞動物衍生產品、生物合成產品）
    • 按應用（慢性傷口與急性傷口）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類 (2022)
  • 產品圖
    • 按類型
    • 按應用
    • 按最終用戶
    • 按地區

第 6 章：北美生物皮膚替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲生物皮膚替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區生物皮膚替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲生物皮膚替代品市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲生物皮膚替代品市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非生物皮膚替代品
    • 沙烏地阿拉伯生物皮膚替代品
    • 阿拉伯聯合大公國生物皮膚替代品

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 類型發布

第 13 章：全球生物皮膚替代品市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代類型的威脅

第15章：競爭格局

  • 商業概覽
  • 產品類型
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Smith & Nephew, plc
    • 3M Company
    • Organogenesis, Inc.
    • Stratatech Corporation
    • Integra LifeSciences Corporation
    • Tissue Regenix Group
    • Mimedx Group

第 16 章：策略建議17。

簡介目錄
Product Code: 15618

In 2022, the biological skin substitutes market reached a valuation of USD 403.09 million, and it is poised to experience robust growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.08% through 2028. This growth can be attributed to several factors, including an escalating incidence of chronic wounds, an expanding geriatric population, and the growing adoption of regenerative medicine techniques.

The market for biological skin substitutes has witnessed significant expansion in recent years, and this trend is anticipated to persist throughout the forecast period. These substitutes find application in the treatment of a diverse array of wounds, encompassing burns, diabetic foot ulcers, and surgical wounds. They are fabricated from a variety of materials, ranging from animal and human tissues to synthetic materials and their combinations.

A prominent driver stimulating growth in the biological skin substitutes market is the escalating occurrence of chronic wounds, particularly prevalent in aging demographics. Chronic wounds are challenging to treat and frequently necessitate interventions exceeding conventional wound care approaches to facilitate proper healing. Concurrently, the demand for advanced wound care products is growing, aiming to enhance healing outcomes and curtail the overall cost of care.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 403.09 Million
Market Size 2028USD 644.13 Million
CAGR 2023-20288.08%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Furthermore, the augmentation of the biological skin substitutes market is facilitated by the mounting embrace of regenerative medicine methodologies. Regenerative medicine employs stem cells and other biologic entities to prompt tissue regeneration and repair. As the domain of regenerative medicine advances, the utilization of biological skin substitutes is poised to become more prevalent.

The expansion of the biological skin substitutes market is also propelled by the introduction of novel products that promise improved healing outcomes and reduced risks of complications. For instance, select biological skin substitutes are engineered to mimic the structural and functional characteristics of natural skin. This emulation can enhance healing outcomes and diminish the likelihood of rejection or infection.

Nonetheless, the market faces challenges stemming from the substantial costs associated with these products. While biological skin substitutes offer tangible advantages over traditional wound care methods, their production costs can be considerable, and insurance coverage may not be universally available. Consequently, access to these products for patients who stand to benefit from them could be restricted.

In spite of these challenges, the trajectory for growth in the biological skin substitutes market remains optimistic. The growing demand for advanced wound care products is anticipated to expedite the development of innovative biological skin substitutes. Moreover, advancements in regenerative medicine and tissue engineering are anticipated to further propel market expansion.

Additionally, the rise in the application of regenerative medicine techniques is bolstering market growth. Regenerative medicine involves the utilization of stem cells and other biologic materials to incite tissue regeneration and repair. The growing popularity of regenerative medicine techniques in the treatment of chronic wounds has led to an increased demand for biological skin substitutes.

Furthermore, there is a growing preference for biological skin substitutes crafted from natural materials, including animal and human tissues. This preference is based on the lower risk of adverse reactions or rejection associated with these natural materials when compared to synthetic alternatives.

The development of pioneering technologies such as 3D printing and tissue engineering is driving innovation within the biological skin substitutes market. These technologies are enabling the creation of intricate and sophisticated skin substitutes that more closely replicate the structure and function of natural skin.

Recent years have witnessed a surge in product launches and developments in the realm of biological skin substitutes. This surge is fueled by the escalating demand for advanced wound care products and the increasing embrace of regenerative medicine techniques.

For instance, Organogenesis, Inc., a prominent provider of regenerative medicine solutions, introduced an updated version of its Apligraf product in 2021. Apligraf is a bi-layered living cell therapy employed in the treatment of diabetic foot ulcers and venous leg ulcers. The enhanced version boasts an extended shelf life and improved handling properties, facilitating ease of use for healthcare providers.

Furthermore, Mallinckrodt Pharmaceuticals, a specialized pharmaceutical company, secured FDA approval for its StrataGraft® product in 2020. StrataGraft® constitutes regenerative skin tissue used to address deep partial-thickness burns. It is created from human cells and designed to closely emulate the structure and functionality of natural skin. This product offers a fresh treatment avenue for patients afflicted with deep partial-thickness burns who may not be suitable candidates for autografting.

In a similar vein, MyOwn Medicines, a regenerative medicine entity, launched MyOwn Skin™ in 2021. MyOwn Skin™ is a personalized skin substitute crafted from the patient's own skin cells. This product is tailored for the treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers. This personalized approach to skin substitutes is poised to enhance healing outcomes while reducing the potential for adverse reactions or rejection.

Increasing Adoption of Regenerative Medicine Techniques

The escalating adoption of regenerative medicine techniques is exerting a profound influence on the expansion of the worldwide market for biological skin substitutes. Regenerative medicine encompasses the utilization of stem cells, growth factors, and other biologic constituents to stimulate the rejuvenation and reparation of tissues.

As the incorporation of regenerative medicine techniques becomes more pervasive, there is an anticipated surge in the requisition for biological skin substitutes. These products play a pivotal role in numerous regenerative medicine strategies and are frequently employed to furnish a structural framework for the revitalization and mending of tissues.

The intensifying interest in regenerative medicine techniques is driving augmented investments in research and development within the field. This impetus is propelling innovation, ultimately culminating in the creation of novel and enhanced biological skin substitutes that offer superior support for tissue rejuvenation and restoration.

The embrace of regenerative medicine techniques is poised to broaden the comprehensive market for biological skin substitutes. The rationale behind this expansion is that these techniques are being harnessed to address a more extensive spectrum of conditions, spanning from chronic wounds and burns to reconstructive surgery.

The application of regenerative medicine techniques, which encompasses the utilization of biological skin substitutes, is closely correlated with enhanced recuperative outcomes. These products have been substantiated to stimulate tissue regeneration and repair, subsequently contributing to expedited recovery periods and ameliorated functional results for patients.

Moreover, regenerative medicine techniques, including the employment of biological skin substitutes, are often associated with cost-effectiveness. By stimulating tissue renewal and mending, these products have the potential to mitigate the necessity for more intricate and costly interventions, such as skin grafts and reconstructive surgery. The growing traction gained by regenerative medicine techniques is significantly shaping the trajectory of the global biological skin substitutes market. As these techniques become more widely integrated, the demand for biological skin substitutes is expected to amplify, thereby catalyzing innovation and fostering the expansion of the overarching market for these products.

Growing Incidences of Chronic Wounds

The escalating prevalence of chronic wounds is a pivotal determinant in shaping the expansion of the worldwide market for biological skin substitutes. Chronic wounds denote wounds that exhibit protracted healing periods and constitute a significant global health concern. They can arise due to an array of factors, encompassing diabetes, impaired circulation, and pressure ulcers. In addressing chronic wounds, biological skin substitutes are garnering increasing attention and are regarded as a promising remedy for this challenge.

As the frequency of chronic wounds surges, there is a concomitant rise in the demand for efficacious treatment alternatives. Within this context, biological skin substitutes emerge as a viable solution and are progressively gaining traction within healthcare domains as providers seek innovative avenues for managing chronic wounds.

Innovations in technology are propelling the creation of novel and enhanced biological skin substitutes that are adept at fostering tissue regeneration and repair. This transformative process is instigating innovation within the market and leading to the formulation of products that manifest heightened effectiveness in addressing chronic wounds.

The augmenting prevalence of chronic wounds is engendering an expansion of the overarching market for biological skin substitutes. These products are being harnessed to combat an increasingly diverse range of conditions, including pressure ulcers, diabetic foot ulcers, and venous leg ulcers.

Biological skin substitutes have demonstrated their capacity to stimulate tissue regeneration and repair, thereby culminating in ameliorated healing outcomes for individuals contending with chronic wounds. This enhancement translates into swifter recovery periods and an improved quality of life for patients grappling with these conditions.

Furthermore, the utilization of biological skin substitutes in the management of chronic wounds can yield economic benefits for healthcare providers. These products possess the potential to curtail the necessity for more invasive and costly interventions, such as skin grafts and reconstructive surgery.

The escalating incidence of chronic wounds constitutes a paramount influencer driving the evolution of the global biological skin substitutes market. As the quest for effective therapeutic alternatives gathers momentum, healthcare providers are increasingly looking to biological skin substitutes as a propitious solution.

Market Segmentation

Global Biological Skin Substitutes market can be segmented on the basis of type, application, end user and region. Based on type, the market can be further divided into human donor tissue-derived products, acellular animal derived products, and biosynthetic products. Based on application, the market is further bifurcated into chronic wounds and acute wounds. Based on end user, the market is divided into hospitals & clinics, ambulatory care centers, and others. On the basis of region, the market is divided into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Smith & Nephew, plc, 3M Company, Organogenesis, Inc., Stratatech Corporation, Integra LifeSciences Corporation, Tissue Regenix Group, Mimedx Group are some of the leading players operating in the global Biological Skin Substitutes market.

Report Scope:

In this report, global Biological Skin Substitutes market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Biological Skin Substitutes Market, By Type:

  • Human Donor Tissue-Derived Products
  • Acellular Animal Derived Products
  • Biosynthetic Products

Biological Skin Substitutes Market, By Application:

  • Chronic Wounds
  • Acute Wounds

Biological Skin Substitutes Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Biological Skin Substitutes Market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biological Skin Substitutes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Human Donor Tissue-Derived Products, Acellular Animal Derived Products, Biosynthetic Products)
    • 5.2.2. By Application (Chronic Wounds v/s Acute Wounds)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Type
    • 5.3.2. By Application
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Biological Skin Substitutes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biological Skin Substitutes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Biological Skin Substitutes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Biological Skin Substitutes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Biological Skin Substitutes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Biological Skin Substitutes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Biological Skin Substitutes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Biological Skin Substitutes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Biological Skin Substitutes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Biological Skin Substitutes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Biological Skin Substitutes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biological Skin Substitutes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Biological Skin Substitutes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Biological Skin Substitutes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Biological Skin Substitutes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Biological Skin Substitutes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Biological Skin Substitutes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biological Skin Substitutes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Biological Skin Substitutes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Biological Skin Substitutes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Biological Skin Substitutes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biological Skin Substitutes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Biological Skin Substitutes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Biological Skin Substitutes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Type Launches

13. Global Biological Skin Substitutes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Type Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Smith & Nephew, plc
    • 15.5.2. 3M Company
    • 15.5.3. Organogenesis, Inc.
    • 15.5.4. Stratatech Corporation
    • 15.5.5. Integra LifeSciences Corporation
    • 15.5.6. Tissue Regenix Group
    • 15.5.7. Mimedx Group

16. Strategic Recommendations17.